Pfenex Awarded Subcontract by Leidos to Develop Malaria Antigen - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfenex Awarded Subcontract by Leidos to Develop Malaria Antigen



Pfenex reports that Leidos Holdings (formerly SAIC) a provider of scientific engineering systems integrations on technical services, has awarded Pfenex a subcontract to develop a robust, scalable, cGMP-ready production process for large-scale production of the blood-stage malaria antigen Plasmodium falciparum reticulocyte-binding homolog 5 (Rh5). This contract is a result of successful preclinical studies performed by Leidos collaborators to evaluate the Rh5 antigen that was produced using the Pfēnex Expression Technology platform. The subcontract is funded with federal funds from Leidos’ prime Malaria Vaccine Production and Support Services contract from the National Institute of Allergy and Infectious Diseases (NIAID)
      
This is the second subcontract awarded to Pfenex for the development of hard-to-express malaria antigens.  Leidos had previously awarded Pfenex a subcontract to develop a scalable, cGMP-ready production process for large-scale production of full-length circumsporozoite protein from P. falciparum. Pfenex will commence process development activities while continuing to provide materials to Leidos and NIAID for ongoing preclinical studies.

Source: Pfenex

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here